Endothelin receptors: Receptor classification, novel receptor antagonists, and potential therapeutic targets

Medicinal Research Reviews

Volumn 16, Issue 4, 1996, Pages 365-390

  Ohlstein, Eliot H ^a   Elliott, John D ^a   Feuerstein, Giora Z ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; BIG ENDOTHELIN 1; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; L 749329; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; RECEPTOR SUBTYPE; RES 701 1; SARAFOTOXIN S6C; TAK 044; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CLASSIFICATION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG RESEARCH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; RECEPTOR BINDING; RESTENOSIS; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ENDOTHELINS; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, ENDOTHELIN;

EID: 0030035774     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(199607)16:4<365::AID-MED4>3.0.CO;2-V     Document Type: Review

References (157)

1. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki, A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, 332, 411 (1988).
2. M. Yanagisawa and T. Masaki, Endothelin, a novel endothelium-derived peptide:pharmacological activities, regulation and possible roles in cardiovascular disease, Biochemical Pharmacol., 38, 1877 (1989).
3. C. Kimura, Y. Itoh, S. Ohklubo, K. Ogi, and M. Fujino, Cloning and sequencing of a canine gene segment encoding mature endothelin, Nucleic Acids Res., 17, 3290 (1990).
4. Z. Wollberg, R. Shabo-Shina, N. Intrator, A. Bdolah, E. Kochva, G. Shavit, Y. Oron, B. A. Vidne, and S. Gitter, A novel cardiotoxic polypeptide from the venom of Atractaspis engaddensis (burrowing asp): cardiac effects in mice and isolated rat and human heart preparations, Toxicon., 26, 525 (1988).
5. A. Bdolah, Z. Wollberg, I. Ambar, Y. Kloog, M. Sokolovsky, and E. Kochva, Disturbances in the cardiovascular system caused by endothelin and sarafotoxin, Biochem. Pharmacol., 38, 3145 (1989).
6. K. D. Bloch, R. L. Eddy, T. B. Shows, and T. Quertermous, cDNA cloning and chromosomal assignment of the gene encoding endothelin 3, J. Biol. Chem., 264, 18156 (1989).
7. T. Arinami, M. Ishikawa, A. Inoue, M. Yanagisawa, T. Masaki, M. C. Yoshida, and H. Hamaguchi, Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to Ip34, and endothelin-3 gene (EDN3) to 20q13.2-q13.3, Am. J. Hum. Genet., 48, 990 (1991).
8. D. Xu, N. Emoto, A. Giaid, C. Slaughter, S. Kaw, D. De Wit, and M. Yanagisawa, ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1, Cell, 78, 473 (1994).
9. H. Arai, S. Hori, I. Aramori, H. Ohkubo, and S. Nakanishi, Cloning and expression of a cDNA encoding an endothelin reeptor, Nature (London), 348, 730 (1990).
10. H. Y. Lin, E. H. Kaji, G. K. Winkel, H. E. Ivs, and H. F. Lodish, Cloning and functional expression of a vascular smooth muscle endothelial 1 receptor, Proc. Natl. Acad. Sci. U.S.A., 88, 3185 (1991).
11. S. Hori, Y. Komatsu, R. Shigemoto, N. Mizuno, and S. Nakanishi, Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors, Endocrinology, 130, 1885 (1992).
12. K. Hosoda, K. Nakao, H. Arai, S.-I. Suga, Y. Ogawa, M. Mukoyama, G. Shirakami, Y. Saito, S. Nakanishi, and H. Imura, Cloning and expression of human endothelin-1 receptor cDNA, FEBS Lett., 287, 23 (1991).
13. N. A. Elshourbagy, D. R. Korman, H. L. Wu, D. R. Sylvester, J. L. Lee, P. Nuthalanganti, D. J. Bergsma, C. S. Kumar, and P. Nambi, Molecular characterization and regulation of the human endothelin receptors, J. Biol. Chem., 268, 3873 (1993).
14. A receptor, Biochem. Biophys. Res. Commun., 1891, 184 (1991).
15. T. Sakurai, M. Yanagisawa, Y. Takuwa, H. Miyazaki, S. Kimura, K. Goto, and T. Masaki, Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor, Nature, 348, 732 (1990).
16. N. A. Elshourbagy, J. A. Lee, D. R. Korman, P. Nuthalaganti, D. R. Sylvester, A. G. Dilella, J. A. Sutiphong, and C. S. Kumar, Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum, Mol. Pharmacol., 41, 465 (1992).
17. B receptor and identification of signal peptidase and metal proteinase cleavage sites, J. Biol. Chem., 266, 23433 (1991).
18. Y. Ogawa, K. Nakao, H. Arai, O. Nakagawa, K. Hosoda, S.-I. Suga, S. Nakanishi, and H. Imura, Molecular cloning of a non-isopeptide-selective human endothelin receptor, Biochem. Biophys. Res. Commun., 178, 248 (1991).
19. M. Nakamuta, R. Takayanagi, Y. Sakai, S. Sakamoto, H. Hagiwara, T. Mizuno, Y. Saito, S. Hirose, M. Yamamoto, and H. Nawata, Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor, Biochem. Biophys. Res. Commun., 177, 34-39 (1991).
20. A receptor, Life Sci., 50, 247 (1991).
21. E. H. Ohlstein, A. Arleth, J. D. Elliott, and C. P. Sung, The selective endothelin-A receptor antagonist BQ-123 antagonizes ET-1 mediated mitogenesis in vascular smooth muscle, Eur. J. Pharmacol. Pharmacol. Section, 225, 350 (1992).
22. E. H. Ohlstein, S. A. Douglas, D. Brooks, D. Hay, G. Z. Feuerstein, and R. R. Ruffolo, Jr., "Functions Mediated by Peripheral Endothelin Receptors," in Endothelin Receptors: From the Gene to the Human, Robert R. Ruffolo, Jr., Ed., CRC Press, 1995, pp. 109-186.
23. B receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation, Eur. J. Pharmacol., 231, 371 (1993).
24. T. D. Warner, G. H. Allcock, R. Corder, and J. Vane, Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the releasae of EDRF, Br. J. Pharmacol., 110, 777-782 (1993a).
25. T. D. Warner, G. H. Allcock, G. H. Mickley, R. Corder, and J. Vane, Comparative studies with endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors, J. Cardiovasc. Pharmacol., 22 (Suppl. 8), S117-S120 (1993b).
26. S. A. Douglas, L. M. Vickery-Clark, and E. H. Ohlstein, Functional evidence that angioplasty results in transient nitric oxide synthase induction, Eur. J. Pharmacol., 225, 81 (1994).
27. E. H. Ohlstein, S. A. Douglas, G. Beck, J. A. Lee, and J. D. Elliot, Pharmacological evidence for the presence of three distinct funtional endothelin receptor subtypes in the rabbit lateral saphenous vein. Brit. J. Pharmacol., 114, 1529 (1995).
28. S. A. Douglas, C. Louden, Vickery-Clark, B. L. Storer, T. Hart, G. Z. Feuerstein, J. D. Elliott, and E. H. Ohlstein, A role for endogenous endothelin-1 in neointima formation following rat carotid artery balloon angioplasaty: Protective effect of the novel nonpeptide endothelin receptor antagonist SB 209670, Circ. Research, 75, 190-197 (1994).
29. S. A. Douglas, G. Beck, P. Nambi, J. G. Gleason, R. R. Ruffolo, Jr., G. Feuerstein, J. D. Eliott, and E. H. Ohlstein, Nonpeptide endothelin receptor antagonists: In vivo pharmacological characterization of SB 209670, Brit. J. Pharmacol., 114, 405-413 (1995).
30. C receptor) from xenopus laevis dermal melanohpores, J. Biol. Chem., 268, 19126 (1993).
31. M. L. Webb, C. C. Chao, M. Rizzo, R. A. Shapiro, M. Neubauer, E.c.K. Liu, C. R. Aversa, R. J. Brittain, and B. Treiger, Cloning and expressiosn of an endothelin receptor subtype B from human prostate that mediated contraction, Mol. Pharmacol., 47, 730-737 (1995).
32. B endothelin receptor, Biochem. Biophys. Res. Commun., 178, 656-665 (1991).
33. C. Kumar, W. Mwangi, P. Nuthulaganti, H.-L. Wu, M. Pullen, K. Brun, H. Aiyar, R. A. Morris, R. Naughton, and P. Nambi, Cloning and characterization of a novel endothelin receptor from xenopus heart, J. Biol. Chem., 269, 13414 (1994).
34. 2-adrenoceptor- and (endothelium-dependent) neuropeptide Y-mediated contractions in the isolated vascular bed of the rat tail, Br. J. Pharmacol, 101, 205 (1990).
35. A. Lerman, B. S. Edwards, J. W. Hallett, D. M. Heublein, S. M. Sandberg, and J. C. Burnett, Jr., Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis, N. Engl. J. Med., 327, 997 (1991).
36. K. Nakayama, Y. Ishigai, H. Uchida, and Y. Tanaka, Potentiation by endothelin-1 of 5-hydroxytrypt-amine-induced contraction in coronary artery of the pig, Br. J. Pharmacol., 104, 978 (1991).
37. P. Nambi, C. Kumar, and E. H. Ohlstein, "Signal Transduction Mechanisms of Endothelin Receptors," in Endothelin Receptors: From the Gene to the Human, Robert R. Ruffolo, Jr., Ed., CRC Press, 1995, pp. 59-77. 1995.
38. E. H. Ohlstein, S. Horohonich, and D. W. P. Hay, Cellular mechanisms of endothelin in rabbit aorta, J. Pharmacol. Expl. Ther., 250, 548 (1989).
39. N. Miasiro, H. Yamamoto, H. Kanaide, and M. Nakamura, Does endothelin mobilize calcium from intracellular store sites in rat aortic vascular smooth muscle cells in primary culture?, Biochem. Biophys. Res. Commun., 156, 312 (1988).
40. C. Van Renterghem, P. Vigne, J. Barhanin, A. Schmid-Alliana, C. Frelin, and M. Lazdunski, Molecular mechanism of action of the vasoconstrictor peptide endothelin, Biochem. Biophys. Res. Commun., 157, 977 (1988).
41. R. A. Bialecki, N. J. Izzo, and W. S. Colucci, Endothelin-1 increases intracellular calcium mobilization but not calcium uptake in rabbit vascular smooth muscle cells, Biochem. Biophys. Res. Commun., 164, 474 (1989).
42. M. Auguet, S. Delaflotte, P. E. Chabrier, and P. C. Braquet, Comparative effects of endothelin and phorbol 12-13 dibutyrate in rat aorta, Life Sci., 45, 2051-2950 (1989).
43. M. Kodama, H. Kanaide, S. Abe, K. Hirano, H. Kai, and M. Nakamura, Endothelin-induced ca-independent contraction of the porcine coronary artery, Biochem. Biophys. Res. Commun., 160, 1302 (1989).
44. A Receptors, J. Biol. Chem., 270(18), 10855-10860 (1995).
45. E. H. Ohlstein and S. A. Douglas, Endothelin-1 modulates vascular smooth muscle structure and vasomotion implications in cardiovascular pathology, Drug. Dev. Res., 29, 108 (1993).
46. E. H. Ohlstein, P. Nambi, S. A. Douglas, R. M. Edwards, M. Gellai, A. Lago, J. D. Leber, R. D. Cousins, A. Gao, J. S. Frazee, C. E. Peishoff, J. W. Bean, D. S. Eggleston, N. A. Elshourbagy, C. Kumar, J. A. Lee, D. P. Brooks, R. R. Ruffolo, Jr., G. Z. Feuerstein, J. Weinstock, J. G. Gleason, and J. D. Elliot, SB 209670, rationally designed potent nonpeptide endothelin receptor antagonist, Proc. Natl. Acad. Sci. U.S.A., 91, 8052 (1994).
47. I. Aramori, H. Nirei, M. Shoubo, K. Sogabe, K. Nakamura, H. Kojo, Y. Notsu, T. Ono, and S. Nakanishi, Subtype Selectivity of a Novel Endothelin Antagonist, FR139317, for the two endothelin receptors in Transfected Chinese Hamster Ovary Cells, Mol. Pharmacol., 43, 127 (1993).
48. A receptor antagonist, J. Pharmacol. Exp. Ther., 264, 1040 (1993).
49. L. O. Cardell, R. Uddman, and L. Edvinsson, A novel ETA-receptor antagonists, FR 139317, inhibits endothelin-induced contraction of guinea pig pulmonary arteries, but not trachea, Br. J. Pharmacol., 108, 448 (1993).
50. A antagonist 5-(Dimthylamio)-N-(3,4,-dimethyl-5-isoxazolyl)-1-napththalene-sulfonamide, J. Med. Chem., 37, 329 (1994).
51. A) receptor-selective antagonists, J. Med. Chem., 38, 1259-1263 (1995).
52. K. Ishikawa, M. Ihara, K. Noguchi, T. Mase, N. Mino, T. Saeki, J. Fukuroda, T. Fukami, S. Ozaki, T. Nagase, M. Nishikibe, and M. Yano, Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788, Proc. Natl. Acad. Sci. U.S.A., 91, 4892 (1994).
53. Y. Morishita, S. Chiba, Tsukuda, T. Tanaka, T. Ogawa, M. Yamasaki, M. Yoshida, I. Kawamoto, and Y. Matsuda, RES-701-1, A novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701, J. Antibiotics, 47, 269-275 (1994).
54. A. M. Doherty, W. L. Cody, P. L. DePue, J. X. He, L. A. Waite, D. M. Leonard, N. L. Leitz, D. T. Dudley, S. T. Rapundalo, G. P. Hingorani, S. J. Haleen, D. M. LaDouceur, K. E. Hill, M. A. Flynn, and E. E. Reynolds, Structure-activity relationships of C-terminal endothelin hexapeptide analogues, J. Med. Chem., 36, 2585-2594 (1993).
55. b, Biochem. Biphys. Res. Commun., 200, 1708-1712 (1994).
56. B-mediated blood pressure responses in rats. The Journal of Pharmacology and Experimental Therapeutics, 270(2), 728-733 (1994).
57. M. Clozel and H. Watanabe, BQ-123, a peptidic endothelin ET(A) receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection, Life Sci., 52, 825-834 (1993).
58. M. Clozel, V. Breu, K. Burri, J.-M. Cassai, W. Fischli, G. A. Gray, G. Hirth, B.-M. Löffler, M. Müller, W. Niedhart, and H. Ramuz, Pathophysiological role of ET revealed by the first orally active ET receptor antagonist, Nature 365, 759 (1993).
59. J. D. Elliott, A. Lago, R. D. Cousins, A. Gao, J. D. Leber, K. Erhard, D. Eggleston, P. Nambi, J. A. Lee, D. P. Brooks, G. Feuerstein, R. R. Ruffolo, Jr., J. Weinstock, J. G. Gleason, C. E. Peishoff, and E. H. Ohlstein, (1S, 2R, 2S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1- yloxy-indane-2-carboxylic acid, a potent and selective non-peptide endothelin receptor antagonist. J. Med. Chem. 37, 1553-1557, (1994).
60. T. F. Walsh, K. Fitch, D. L. Williaams, K. L. Murphy, N. A. Nolan, D. J. Pettibone, R. S. L. Chang, S. S. O'Malley, B. V. Clineschmidt, D. F. Veber, and W. J. Greenlee, Potent dual antagonists of endothelin and angiotensin II receptors derived from alpha-phenoxyphenylactetic acids (Part III), Bioorg. Med. Chem. Lett., 5, 1155 (1995).
61. Y. Tomobe, T. Ishikawa, M. Yanagisawa, S. Kimura, T. Masaki, and K. Goto, Mechanisms of altered sensitivity to endothelin-1 between aortic smooth muscles of spontaneously hypertensive and Wistar-Kyoto rats, J. Pharmacol. Expl. Ther., 257, 555 (1991).
62. N. Suzuki, T. Miyauchi, Y. Tomobe, H. Matsumoto, K. Goto, T. Masaki, and M. Fujino, Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats, Biochem. Biophys. Res. Commun., 167, 941 (1990).
63. C. E. Wright and J. R. Fozard, Differences in regional vascular sensitivity to endothelin-1 between spontaneously hypertensive and normotensive Wistar-Kyoto rats, Br. J. Pharmacol. 100, 107 (1990).
64. Y. Saito, K. Nakao, M. Mukoyama, and H. Imura, Increased plasma endothelin level in patients with essential hypertension, N. Engl. J. Med., 322, 205 (1989).
65. A. P. Davenport, M. J. Ashby, P. Easton, S. Ella, J. Bedford, C. Dickerson, D. J. Nunez, S. J. Capper, and M. J. Brown, A sensitive RIA measuring ET-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertensen and normotensive subjects, Clin. Sci., 78, 261 (1990).
66. M. Kohno, K. Yasunari, K. I. Murakawa, K. Yokokawa, T. Horio, T. Fujui, and T. Takeda, Plasma immunoreactive endothelin in essential hypertension, Am. J. Med., 88, 164 (1990).
67. M. Shichiri, Y. Hirata, K. Ando, T. Emori, K. Ohta, S. Kimoto, M. Ogura, A. Inoue, and F. Marumo, Plasma endothelin levels in hypertension and chronic renal failure, Hypertens., 15, 493 (1990).
68. A. Ohno, M. Naruse, S. Kato, M. Hosaka, K. Karuse, and H. Demura, Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats, J. Hypertension, 10, 781 (1992).
69. M. Nishikibe, S. Tsuchida, M. Okada, T. Fukuroda, K. Shimamoto, and M. Yano, Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model, Life Sci., 52, 717 (1993).
70. E. H. Ohlstein, S. A. Douglas, M. Ezekiel, and M. Gellai, Antihypertensive effects of the endothelin antagonist BQ-123 in conscious spontaneously hypertensive rats, J. Cardiovasc. Pharmacol., 22 (Suppl. 8), S321 (1993).
71. J. E. Bird, S. Moreland, T. L. Waldron, and J. R. Powell, Antihypertensive Effects of Novel Endothelin-A Receptor Antagonist in Rats, Hypertension, 25(6), 1191-1195 (1995).
72. M. Fukui, T. Nakamura, J. Ebihara, S. Osada, Y. Tomino, T. Masaki, K. Goto, Y. Furuichi, and H. Koide, Gene expression for ETs and their receptors in glomeruli of diabetic rats, J. Lab. Clin. Med., 122, 149 (1993).
73. E. Morabito, N. Corsico, S. Serafini, and E. A. Arrigoni Martelli, Elevated urinary excretion of endothelins in streptozotocin diabetic rats, Life Sci., 54, 197 (1994).
74. A. Hemsén, A. Franco-Cereceda, R. Matran, A. Rudehill, and J. M. Lundberg, Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue, Eur. J. Pharmacol., 191, 319 (1990).
75. P. J. Henry, P. J. Rigby, G. J. Self, J. M. Preuss, and R. G. Goldie, Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle, Br. J. Pharmacol., 100, 786 (1990).
76. T. J. Stelzner, R. F. O'Brien, M. Yanagisawa, T. Sakurai, K. Sato, S. Webb, M. Zamora, I. Yamaguchi, I. F. McMeetry, and J. Fisher, Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension, Am. J. Physiol., 262, L614 (1992).
77. T. Miyauchi, R. Yorikane, S. Sakai, T. Sakurai, M. Okada, M. Nishikibe, M. Yano, I. Yamaguchi, Y. Sugishita, and K. Goto, Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension, Circ. Res., 73, 887 (1993).
78. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats, Am. J. Physiol., 266, H1327 (1994).
79. R. N. Willette, G. Z. Feuerstein, and F. C. Barone, "Endothelin in the central nervous system," in Endothelin Receptors: From the Gene to the Human, R. R. Ruffolo, Jr., Ed., Humana Press: New York, 1995, in press 1995.
80. P. G. Cavero, W. L. Miller, D. M. Heublein, K. B. Margulies, and J. C. Burnett, Endothelin in experimental congestive heart failure in the anesthetized dog. Am. J. Physiol., 259, F312 (1990).
81. R. M. Robertson, T. Susawa, M. Sugiura, V. Haile, and T. Inagami, Circulating endothelin levels: modulation by heart failure in man, Clin. Res., 38, 414A (1990).
82. L.-X. Fu, X.-Y. Sun, T. Hedner, Q.-P. Feng, Q.-M. Liang, J. Hoebeke, and A. Hjalmarson, Decreased density of mesenteric arteries but not of myocardial endothelin receptors and function in rats with chronic ischemic heart failure, J. Cardiovasc. Pharmacol., 22, 177 (1993).
83. K. B. Margulies, F. L. Hildebrand, A. Lerman, M. A. Perrella, and J. C. Burnett, Increased endothelin in experimental heart failure, Circulation, 2, 2226 (1990).
84. J. R. Teerlink, J.P. Clozel, B. M. Löffler, W. Fischli, and M. Clozel, Evolution of plasma endothelin and renin activity levels in a rat model of congesetive heart failure, Circulation, 86, I-430 (1992).
85. B.-M. Löffler, S. Roux, B. Kalina, M. Clozel, and J.-P. Clozel, Influence of congestive heart failure on endothelin levels and receptors in rabbits, J. Mol. Cell. Cardiol., 25, 407 (1993).
86. R. Yorikane, S. Sakai, T. Miyauchi, T. Sakurai, Y. Sugishita, and K. Goto, Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett., 332, 31 (1993).
87. M. Arai, A. Yoguchi, T. Iso, T. Takahashi, S. Imo, K. Murata, and T. Susuki, Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy, American Physiological Society, H2084-H2091 (1995).
88. H. Ito, Y. Hirata, M. Hiroe, M. Tsujino, S. Adachi, T. Takamoto, M. Nitta, K. Taniguchi, and F. Marumo, Endothelin-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured neonatal rat cardiomyocytes, Circ. Res., 69, 209 (1991).
89. H. E. Shubeita, P. M. Mcdonough, A. N. Harris, K. U. Knowlton, C. C. Glembotski, J. H. Brown, and K. R. Chien, Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hyperterophy, J. Biol. Chem., 265, 20555 (1990).
90. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload, Circulation, 89, 2198 (1994).
91. H. Yoshimi, Y. Hirata, Y. Fukuda, Y. Kawano, T. Emori, M. Kuramochi, T. Omae, and F. Marumo, Regional distribution of immunoreactive endothelin in rats, Peptides, 10, 805 (1989).
92. B. M. Wilkes, M. Susin, P. F. Mento, C. M. Macica, E. P. Girardi, E. Boss, and E. P. Nord, Localization of ET-like immunoreactivity in rat kidneys, Am. J. Physiol., 260, F913 (1991).
93. J. Pernow, A. Franco-Cereceda, R. Matran, and J. M. Lundberg, Effect of ET-1 on regional vascular resistances in the pig, J. Cardiovasc. Pharmacol., 13 (Suppl. 5), S205 (1989).
94. P. Madeddu, X.-P. Yang, V. Anania, C. Troffa, A. Pazzola, A. Soro, P. Manunta, G. Tonolo, M. P. Demontis, M. V. Varoni, M. G. Melis, and N. Glorioso, Efficacy of nifedipine to prevent systemic and renal vasoconstrictor effects of ET, Am. J. Physiol., 259, F304 (1990).
95. V. Kon, T. Yoshioka, A. Fogo, and I. Ichikawa, Glomerular actions of ET in vivo, J. Clin. Invest., 83, 1762 (1989).
96. S. S. Sorensen, J. K. Madsen, and E. B. Pedersen, Systemic and renal effect of intravenous infusion of ET-I in healthy human volunteers, Am. J. Physiol., 35, F411 (1994).
97. + exchange, c-fos expression, and mitogenesis in rat mesangial cells, J. Clin. Invest., 83, 708 (1989).
98. F. E. Jaffer, T. C. Knauss, E. Poptic, and H. E. Abboud, Endothelin stimulates PDGF secretion in cultured human mesangial cells, Kidney Int. 38, 1193 (1990).
99. V. Kon and K. F. Badr, Biological actions and pathophysiologic significance of ET in the kidney, Kidney Int., 40, 1 (1991).
100. D. E. Kohan, Endothelins in the kidney: physiology and pathophysiology, Am. J. Kidney Dis., 22, 493 (1993).
101. T. A. Marsen, H. Schramek, and M. J. Dunn, Renal actions of ET: linking cellular signaling pathways to kidney disease, Kidney Int., 45, 336 (1994).
102. N. Mino, M. Kobayashi, A. Nakajima, H. Amano, K. Shimamoto, K. Ishikawa, K. Watanbe, M. Nishikebe, M. Yano, and F. Ikemoto, Protective effect of a selective ET receptor antagonist, BQ123, in ischemic acute renal failure in rats, Eur. J. Pharmacol., 221, 77 (1992).
103. M. Gellai, M. Jugus, T. A. Fletcher, P. Nambi, D. P. Brooks, E. H. Ohlstein, J. D. Elliot, J. Gleason, and R. R. Ruffolo, Jr., The ET receptor antagonist, (±)-SB 209670, reverses ischemia-induced acute renal failure (ARF) in the rat, FASEB J., 8, A260 (abst.) (1994).
104. K. Kusumoto, K. Kubo, H. Kandori, T. Kitayoshi, S. Sato, M. Waskimasu, T. Watanabe, and M. Fujino, Effects of a new endothelin antagonists, TAK-044, on post-oscemic acute renal failure in rats, Life Sciences 55(4), 301-310 (1994).
105. D. F. Brooks, P. D. DePalms, M. Pullen, and P. Nambi, Characterization of canine renal ET receptor subtypes and their function, J. Pharmacol. Exp. Ther., 268, 1091 (1994).
106. V. Kon, M. Sugiura, T. Inagami, B. R. Harvie, I. Ichikawa, and R. L. Hoover, Role of ET in cyclosporine-induced glomerular dysfunction, Kidney Int., 37, 1487 (1990).
107. I. T. M. Bloom, F. R. Bentley, and R. N. Garrison, Acute cyclosporine-induced renal vasoconstriction is mediated by ET-1, Surgery, 114, 480 (1993).
108. N. Perico, J. Dadan, and G. Remuzzi, Endothelin mediates the renal vasoconstriction induced by cyclospirine in the rat, J. Am. Soc. Nephrol., 1, 76 (1990).
109. A. Fogo, S. E. Hellings, T. Inagami, and V. Kon, Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity, Kidney Int., 42, 770 (1992).
110. D. P. Brooks and L. C. Contino, Prevention of cyclosporine-induced vasoconstriction by the ET antagonist SB 209670, Eur. J. Pharmacol., (submitted) (1995).
111. M. Takeda, M. D. Breyer, T. D. Noland, T. Homma, R. L. Hoover, T. Inagami, and V. Kon, Endothelin-1 receptor antagonist: effects on ET- and cyclosporine-treated mesangial cells, Kidney Int., 42, 1713 (1992).
112. L. G. Cantley, K. Spokes, B. Clark, E. G. McMahon, J. Carter, and F. H. Epstein, Role of ET and prostaglandins in radiocontrast-induced renal artery constriction, Kidney Int., 44, 1217 (1993).
113. H. Koyama, Y. Nishzawa, H. Morii, T. Tabata, T. Inoue, and T. Yamaji, Plasma ET levels in patients with uraemia, Lancet, May 6, 991, (1989).
114. H. Predel, H. Meyer-Lehnert, A. Bäcker, H. Stelkens, and H. J. Kramer, Plasma concentrations of ET in patients with abnormal vascular reactivity, Life Sci., 47, 1837 (1990).
115. F. Stockenhuber, M. Gottsauner-Wolf, L. Marosi, B. Liebisch, R. W. Kurz, and P. Balcke, Plasma levels of ET in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity, Clin. Sci., 82, 255 (1992).
116. D. P. Brooks, L. C. Contino, B. Storer, and E. H. Ohlstein, Increased ET excretion in rats with renal failure induced by partial nephrectomy, Br. J. Pharmacol., 104, 987 (1991).
117. A. Benigni, N. Perico, F. Gaspari, C. Zoja, L. Bellizzi, M. Gabanelli, and G. Remuzzi, Increased renal ET production in rats with reduced renal mass, Am. J. Physiol., 260, F331 (1991).
118. S. Orisio, A. Benigni, I. Bruzzi, D. Corna, N. Perico, C. Zoja, L. Benatti, and G. Remuzzi, Renal ET gene expression is increased in remnant kidney and correlates with disease progression, Kidney Int., 43, 354 (1993).
119. A. Benigni, C. Zoja, D. Corna, S. Orisio, L. Longaretri, T. Bertani, and G. Remuzzi, A specific ET subtype A receptor antagonist protects against injury in renal disease progression, Kidney Int., 44, 440 (1993).
120. F. Martin-Nizard, H. S. Houssaini, S. Lestavel-Delattre, P. Duriez, and J.-C. Fruchart, Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin, FEBS Lett., 293, 127 (1991).
121. C. M. Boulanger, F. C. Tanner, M.-L. Beau, A. W. A. Han, A. Werner, and T. F. Lüscher, Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium, Circ. Res., 70, 1191 (1992).
122. J. A. G. Lopez, M. L. Armstrong, D. J. Piegors, and D. D. Heistad, Vascular responses to endothelin-1 in atherosclerotic primates, Arteriosclerosis, 10, 1113 (1990).
123. M. G. Davies, M. L. Klyachkin, J. H. Kim, and P.-O. Hagen, Endothelin and vein bypass grafts in experimental atherosclerosis, J. Cardiovasc. Pharmacol., 22 (Suppl. 8), S348-S351 (1993).
124. 125I-endothelin-1 accumulation in experimental arterial wall injury, Eur. J. Nucl. Med., 20, 1141 (1993).
125. 125I]Endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimai hyperplasia and atherosclerosis, J. Cardiovasc. Pharmacol., 22 (Suppl. 8), S343 (1993).
126. 125I]-ET-1 binding to the atherosclerotic human coronary artery, Br. J. Pharmacol., 112, 386 (1994).
127. X. Wang, S. A. Douglas, and E. H. Ohlstein, The use of quantitative RT-PCR to demonstrate the increased expression of endothelin-related mRNA's following angioplasty-induced neointima formation in the rat. Circulation Research 78, 322 (1996).
128. M. Tsujino, Y. Hirata, S. Eguchi, T. Watanabe, F. Chatani, and F. Marumoi, Nonselective ETA/ETB receptor antagonits blockes proliferation of rat vasclar smooth muscle cells after ballon angioplasry, Life Sci., 56, PL449-PL454 (1995).
129. J. Wesale, A. Adler, E. Novosad, S. Burke, B. Dayton, and T. Opgenorth, Endothelin antagonism reduced neointima formed following balloon injury in rabbit. Abstracts from the Fourth International Conference on Endothelin, London, April, 1995.
130. T. Jenkins-West, M. Valentine, S. Moreland, and P. Ferrer, Intimal lesion development in baloon injured rat carotid arteries is suppressed by the endothelin receptor antagonists BMS-182874, FASEB. J., 9, A343 (1995).
131. B receptor in the rat carotid artery balloon angioplasry model. Cardiovascular Res. 29, 641-646 (1995).
132. M. Kowala, P. Rose, P. Stein, N. Goller, R. Recce, S. Beyer, M. Valentine, D. Barton, and S. Durham, Selective blockade of the endothelin subtype A receptor decrease early atherosclerosis in hamsters fed cholesterol, Am. J. Path., 146, 819-826 (1995).
133. G. J. Grover, P. G. Sleph, M. Fox, and N. C. Trippodo, Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts, J. PharmacoL Exp. Ther., 263, 1074 (1992).
134. T. Watanabe, N. Suzuki, N. Shimamoto, M. Fujino, and A. Imada, Endothelin in myocardial infarction, Nature, 344, 114 (1990).
135. K. Kusumoto, S. Fujiwara, Y. Awane, and T. Watanabe, The role of endogenous endothelin in extension of rabbit myocardial infarction, J. Cardiovasc. Pharmacol., 22 (Suppl. 8), S339 (1993).
136. A receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischemia and reperfusion, Br. J. Pharmacol., 112, 75 (1994).
137. R. A. Nelson, S. E. Burke, and T. Opgenorth, Endothelin receptor antagonist fr139317 reduces infarct size in a rabbit coronary artery occlusion model, FASEB J., 8, A854 (1994).
138. A receptor antagonist FR 139317 reduces myocardial infarction induced by coronary artery occlusion and reperfusion in the rat, FASEB J., 8, A854 (1994).
139. B receptor antagonists, TAK-044 and the inhibition of myocardial infarct size in rats, British Journal of Pharmacology, 114, 949-954 (1995).
140. T. Yamauchi, K. Ohnaka, and R. Takakyanagi, Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells, FEBS Lett., 267, 16 (1990).
141. F. J. Oliver, G. De La Rubia, and E. Feener, Stimulation of endothein-1 gene expression by insulin in endothelial cells, J. Biol. Chem., 266, 23251 (1991).
142. C. F. Kwok, M. L. Chen, and L. T. Ho, Insulin increases the endothelin-1 receptor in cultured rat aortic smooth muscle cells, Diabetalog., 36 (Suppl. 1), A203 (1993).
143. K. Totsune, M. Sone, K. Takahashi, M. Ohneda, K. Itoi, O. Murakami, T. Saito, T. Mouri, and K. Yoshinaga, Immunoreactive endothelin in urine of patients with and without diabetes mellitus, J. Cardiovasc. Pharmacol., 17 (Suppl. 7), S423 (1991).
144. G. Kirilov, L. Dakovska, A. M. Borisova, S. Krivoshiev, and N. Nentchev, Increased plasma endothelin levels in patients with insulin-dependente diabetes mellitus and end-stage vascular complications, Horm. Metab. Res., 26, 119 (1994).
145. M. Awazu, M. Sugiura, T. Inagami, I. Ichikawa, and V. Kon, Cyclosporine promotes glomerular ET binding in vivo, J. Am. Soc. Nephrol., 1, 1253 (1991).
146. w-nitro-L-arginine methyl ester in streptozotocin-induced diabetes mellitus, Br. J. Pharmacol., 106, 1035 (1992).
147. E. J. Stevens and D. R. Tomlinson, Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes, Br. J. Pharmacol., 115, 373-379 (1995).
148. F. C. Barone, R. N. Willette, T. L. Yue, and G. Feuerstein, Therapeutic effects of endothelin receptor antagonists in stroke, Neurol. Res., in press (1995).
149. R. N. Willette, H. Zhang, M. P. Mitchell, C. F. Sauermelch, E. H. Ohlstein, and A. C. Sulpizio, Nonpeptide endothelin antagonist: cerebrovascular characterization and effects on delayed cerebral vasospasm, Stroke, 25, 2450-2456 (1994).
150. K. Fuxe, N. Kurosawa, A. Cintra, A. Hallström, M. Goiny, L. Rosen, M. Goldstein, and L. F. Agnati, Involvement of local ischemia in endothelin-1
151. M. J. Robinson, I. M. Macrae, M. Todd, J. L. Reid, and J. McCulloch, Reduction of local cerebral blood flow to pathological levels by endothelin-1 applied to the middle cerebral artery in the rat, Neurosci. Lett., 118, 269-272 (1990).
152. I. Yamaura, E. Tani, Y. Maeda, N. Minami, and H. Shindo, Endothelin-1 of canine basilar artery in vasospasm, J. Neurosurg., 76, 99-105 (1992).
153. H. Nirei, K. Hamada, M. Shoubo, K. Sogabe, Y. Notsu, and T. Ono, An endothelin ET-A receptor antagonist, FR 139317, ameliorates cerebral vasospasm in dogs, Life. Sci., 52, 1869-1874 (1993).
154. K. Togashi, Y. Hirata, K. Ando, T. Matsunago, M. Kawakami, and F. Marumo, Abundance of endothelin-3 in human cerebrospinal fluid, Biomed. Res., 11, 243 (1990).
155. I. Ziv, G. Fleminger, R. Dyaldetti, A. Achiron, E. Melamed, and M. Sokolovsky, Increased plasma endothelin-1 in acute ischemic stroke, Stroke, 23, 1014-1016 (1992).
156. G. Z. Feuerstein, J.-L. Gu, E. H. Ohlstein, F. C. Barone, and T.-L. Yue, Peptidic endothelin-1 receptor antagonist, BQ-123, and neuroprotection, Peptides, 15, 467-469 (1994).
157. T. Omland, T. T. Lie, A. Aakvaag, T. Assrsland, and K. Dickstein, Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction, Circulation, 89, 1573-1579 (1994).